Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure

Gagandeep Kang; Anand Lakhkar; Chetanraj Bhamare; Abhijeet Dharmadhikari; Jyoti Narwadkar; Arti Kanujia; Dhananjay Kapse; Bhagwat Gunale; Cyrus S Poonawalla; Prasad S Kulkarni

doi:10.1016/j.lansea.2023.100207

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure

Lancet Reg Health Southeast Asia. 2023 May 16:14:100207. doi: 10.1016/j.lansea.2023.100207. eCollection 2023 Jul.

Affiliations

¹ Translational Health Science and Technology Institute, Faridabad, India.
² Serum Institute of India Pvt Ltd, Pune, India.
³ LabCorp Scientific Services & Solutions Pvt Ltd, Mumbai, India.

Abstract

Background: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing surveillance was conducted in India from 2020 to 2021 to gather real world safety data on Rabivax-S and Rabishield.

Methods: This was non-interventional active surveillance in patients with category III potential rabies exposure who were administered a post-exposure prophylaxis (PEP) regimen (Rabishield and Rabivax-S) by their healthcare providers (HCPs) as per the dosages and regimens mentioned in the package insert approved by the Indian regulators. The approved schedule for PEP was local infiltration of Rabishield on Day 0 and five doses of Rabivax-S on Day 0, 3, 7, 14, and 28 (Intramuscular route, IM) or four doses of Rabivax-S on Day 0, 3, 7, and 28 (Intradermal route, ID). The primary objective of this surveillance was to generate real-world evidence on the safety and tolerability of Rabishield and Rabivax-S. All patients enrolled in the surveillance were required to report any adverse events (AEs) occurring up to Day 31 after initiation of PEP (administration of Rabishield and the first dose of Rabivax-S) to their HCP.

Findings: A total of 1000 patients with category III potential rabies exposure were enrolled across India. 991 patients received the PEP regimen with IM Rabivax-S while 9 received a PEP regimen with the ID regimen. While 32% of the patients were <12 years of age, 11.8% were ≥12 to <18 years of age and 56.2% were ≥18 years of age. The entire PEP regimen was completed by 97.3% of the enrolled patients. A total of 69 AEs were reported in 64 patients. Out of these, 49 AEs in 47 patients were assessed as causally related to the study products (26 with Rabishield and 23 with Rabivax-S). The majority of the AEs were mild and all recovered without any sequelae. One serious adverse event (SAE) of fracture of the hand was reported which was not related to either Rabishield or Rabivax-S. No case of rabies was reported.

Interpretation: Rabishield and Rabivax-S have an excellent safety profile and are well tolerated. No participant developed rabies during 31 day follow up.

Funding: The PMS was funded by Serum institute of India Private Limited which is the manufacturer of the study products.

Keywords: Post-marketing surveillance; Rabies human monoclonal antibody; Rabies vaccine; Safety.